16508-04-6

Basic information

• Product Name: bicyclo[2.2.1]hept-2-ene-2,3-dicarboxylic acid
• CAS NO: 16508-04-6
• Molecular Formula: C₉H₁₀O₄
• Molecular Weight: 182.1733
• Mol File: 16508-04-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 374.2°C at 760 mmHg
• Flash Point: 194.3°C
• Density: 1.53g/cm³
• Vapor Pressure: 1.25E-06mmHg at 25°C
• Refractive Index: 1.626
• CAS DataBase Reference: bicyclo[2.2.1]hept-2-ene-2,3-dicarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: bicyclo[2.2.1]hept-2-ene-2,3-dicarboxylic acid(16508-04-6)
• EPA Substance Registry System: bicyclo[2.2.1]hept-2-ene-2,3-dicarboxylic acid(16508-04-6)

Safety Data

• Hazardous Substances Data: 16508-04-6(Hazardous Substances Data)

Upstream product

• 15872-28-3 bicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylic acid 
• 947-57-9 dimethyl bicyclo[2.2.1]hept-2,5-diene-2,3-dicarboxylate 
• 17931-56-5 Dimethyl Bicyclo<2.2.1>hept-2-ene-2,3-dicarboxylate 
• 33140-59-9 (1R,2S,3R,4S)-2,3-dibromobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic anhydride 
• 542-92-7 cyclopenta-1,3-diene 

Downstream Products

• 2435-37-2 norbornane-2endo,3endo-dicarboxylic acid 
• 1560642-78-5 C₂₇H₃₀ClN₅O₂ 
• 1560642-79-6 C₄₃H₅₀N₈O₄ 
• 1561214-03-6 C₃₃H₃₄N₈ 
• 1560649-16-2 C₄₇H₅₆N₁₀O₆ 
• 73679-39-7 anti-1,2,3,4,5,6,7,8-octahydro-1,4,5,8-dimethano-naphthalene anti-sesquinorbornene 

Relevant articles and documents

THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby improving properties of

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.